It was proved that miR-101 expression was significantly associated with pathological stage and lymph node involvement, and might play an important role as a biomarker for prognosis and therapeutic targets of NSCLC [39], (through directly targeting enhancer of zeste homolog 2(EZH2) [40]). This evidence concerns the gene EZH2 and non-small cell lung carcinoma.